Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 22, 2024Cancer Research

Abstract 1890: HMA800067, a novel CD38-targeting antibody-drug conjugate (ADC), demonstrated superior anti-tumor activity to daratumumab in preclinical B-cell malignancies models

View Full Paper
Ask AI
Bookmark
Share

Authors

YXYan XuJLJunqing LiangSJShuwen Jiang

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Xu et al. (2024) studied this question.

synapsesocial.com/papers/68e72e1db6db6435876a727fhttps://doi.org/10.1158/1538-7445.am2024-1890
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Leveraging novel CD38 targeted antibody-drug-conjugates for the treatment of multiple myeloma2025 · 1 citations
  2. 2Abstract CT133: First-in-human trial of 225Actinium-DOTA-daratumumab, an alpha-emitting radioimmunotherapy, in patients with daratumumab-refractory multiple myeloma2026
  3. 3Abstract 1223: KDM6A orchestrates NK cell response <i>via</i> CD38/48 regulation in multiple myeloma2024
  4. 4High-Dimensional Spectral Analysis of Natural Killer Cell Alterations Identifies a Subgroup with an Enhanced Daratumumab Treatment Response in Relapsed and Refractory Multiple Myeloma2024 · 1 citations
  5. 5Abstract 1237: IGM-2644, a CD38xCD3 bispecific IgM T cell engager, shows enhanced anti-tumor activity compared to daratumumab in preclinical models of multiple myeloma2024 · 1 citations